The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

NCT07073833 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: IBR900 cell injection
DRUG: rituximab

Sponsor

Imbioray (Hangzhou) Biomedicine Co., Ltd.